Home 
Today's Top Picks 
Top Performers 
Watchlist 
My Robo Portfolios 
ETF Zone 
Help & Tutorial 
Cancel anytime
- Chart
- Upturn Summary
- Highlights
- Valuation
- Analyst Ratings
Upturn AI SWOT - About
Vicarious Surgical Inc. (RBOT)
- BUY Advisory
- SELL Advisory (Profit)
- SELL Advisory (Loss)
- Profit
- Loss
- Pass (Skip investing)
Stock price based on last close (see disclosures)
- ALL
- YEAR
- MONTH
- WEEK
Upturn Advisory Summary
06/27/2025: RBOT (1-star) is currently NOT-A-BUY. Pass it for now.
Upturn Star Rating
Not Recommended Performance
These Stocks/ETFs, based on Upturn Advisory, consistently fall short of market performance, signaling caution before investing.
Number of Analysts
3 Analysts rated it
Limited analyst coverage, niche firm, research info may be scarce.
1 Year Target Price $10.75
1 Year Target Price $10.75
| 1 | Strong Buy |
| 0 | Buy |
| 2 | Hold |
| 0 | Sell |
| 0 | Strong Sell |
Analysis of Past Performance
Type Stock | Historic Profit -20.84% | Avg. Invested days 29 | Today’s Advisory PASS |
Upturn Star Rating | Upturn Advisory Performance  2.0 | Stock Returns Performance  1.0 |
| Profits based on simulation | Last Close 06/27/2025 |
Key Highlights
Company Size Small-Cap Stock | Market Capitalization 45.14M USD | Price to earnings Ratio - | 1Y Target Price 10.75 |
Price to earnings Ratio - | 1Y Target Price 10.75 | ||
Volume (30-day avg) 3 | Beta 1.42 | 52 Weeks Range 4.27 - 19.00 | Updated Date 06/29/2025 |
52 Weeks Range 4.27 - 19.00 | Updated Date 06/29/2025 | ||
Dividends yield (FY) - | Basic EPS (TTM) -10.44 |
Earnings Date
Report Date - | When - | Estimate - | Actual - |
Profitability
Profit Margin - | Operating Margin (TTM) - |
Management Effectiveness
Return on Assets (TTM) -51.6% | Return on Equity (TTM) -104.36% |
Valuation
Trailing PE - | Forward PE - | Enterprise Value 21285774 | Price to Sales(TTM) - |
Enterprise Value 21285774 | Price to Sales(TTM) - | ||
Enterprise Value to Revenue - | Enterprise Value to EBITDA 0.41 | Shares Outstanding 5278180 | Shares Floating 3104978 |
Shares Outstanding 5278180 | Shares Floating 3104978 | ||
Percent Insiders 27.08 | Percent Institutions 34.2 |
Analyst Ratings
Rating 2 | Target Price 10.75 | Buy - | Strong Buy 1 |
Buy - | Strong Buy 1 | ||
Hold 2 | Sell - | Strong Sell - | |
Strong Sell - |
Upturn AI SWOT
Vicarious Surgical Inc.
Company Overview
History and Background
Vicarious Surgical Inc. was founded in 2014. It focuses on developing surgical robots that combine human-like dexterity with the precision of robots to improve patient outcomes and reduce healthcare costs. The company went public through a SPAC merger in 2021.
Core Business Areas
- Robotic Surgery System Development: Development and commercialization of a surgical robot system designed for minimally invasive surgery with enhanced visualization and dexterity.
Leadership and Structure
Adam Sachs is the CEO. The company operates with a functional structure, with teams focused on engineering, research, manufacturing, and commercial operations.
Top Products and Market Share
Key Offerings
- Vicarious Surgical System (under development): The company's flagship product, a surgical robot system designed to enhance visualization and dexterity in minimally invasive procedures. It is currently not commercially available. The company is targeting a large portion of soft tissue surgery which has a substantial TAM, and the competitors are Intuitive Surgical (ISRG), Stryker (SYK), Medtronic (MDT).
Market Dynamics
Industry Overview
The surgical robotics industry is growing rapidly, driven by demand for minimally invasive procedures, improved surgical precision, and reduced recovery times. Technological advancements and an aging population contribute to this growth.
Positioning
Vicarious Surgical aims to differentiate itself through its human-like dexterity and enhanced visualization capabilities, allowing surgeons to perform a wider range of procedures with minimal invasiveness. They are a smaller player aiming to disrupt the established market leaders.
Total Addressable Market (TAM)
The TAM for robotic surgery is estimated to be in the tens of billions of dollars. Vicarious Surgical is targeting a substantial portion of the soft tissue surgery market, positioning itself to capture a significant share with successful commercialization.
Upturn SWOT Analysis
Strengths
- Innovative robotic surgery technology
- Strong intellectual property portfolio
- Experienced management team
- Potential to expand the range of minimally invasive procedures
Weaknesses
- Pre-revenue stage, relying on fundraising
- High capital expenditure requirements
- Dependence on regulatory approvals
- Limited commercial experience
Opportunities
- Expanding applications of robotic surgery
- Partnerships with hospitals and healthcare providers
- Acquisitions and strategic alliances
- Geographic expansion into international markets
Threats
- Competition from established players
- Technological obsolescence
- Regulatory hurdles and delays
- Economic downturns impacting healthcare spending
Competitors and Market Share
Key Competitors
- ISRG
- SYK
- MDT
- ROBO
Competitive Landscape
Vicarious Surgical faces intense competition from established players with significant market share, resources, and existing customer relationships. Its competitive advantage lies in its innovative technology and potential to offer a more versatile and cost-effective solution.
Growth Trajectory and Initiatives
Historical Growth: As a pre-revenue company, historical growth is measured by progress in product development, regulatory approvals, and partnerships. Recent advancements showcase the potential for growth.
Future Projections: Future growth projections are based on the successful commercialization of its robotic surgery system and adoption by healthcare providers. Analyst estimates vary widely due to the uncertainty surrounding regulatory approvals and market acceptance.
Recent Initiatives: Recent initiatives include securing regulatory designations (e.g., Breakthrough Device designation), expanding the engineering team, and conducting clinical trials to validate the system's safety and efficacy.
Summary
Vicarious Surgical is a pre-revenue surgical robotics company with innovative technology but faces significant challenges in a competitive market. While the company has strengths in technology and intellectual property, weaknesses include its pre-revenue stage and high capital expenditure requirements. The company needs to watch out for competition from established players and potential regulatory hurdles. Growth will depend on securing regulatory approvals and commercializing its product successfully.
Peer Comparison
Sources and Disclaimers
Data Sources:
- Company filings (SEC), Investor presentations, Analyst reports, Industry reports
Disclaimers:
This analysis is based on publicly available information and analyst estimates, which are subject to change. It is not financial advice.
AI Summarization is directionally correct and might not be accurate.
Summarized information shown could be a few years old and not current.
Fundamental Rating based on AI could be based on old data.
AI-generated summaries may have inaccuracies (hallucinations). Please verify the information before taking action.
About Vicarious Surgical Inc.
Exchange NYSE | Headquaters Waltham, MA, United States | ||
IPO Launch date 2020-09-04 | Co-Founder, CEO & Director Mr. Adam David Sachs | ||
Sector Healthcare | Industry Medical Devices | Full time employees 123 | |
Full time employees 123 | |||
Vicarious Surgical Inc. develops and sells single-port surgical robot in the United States. It offers Vicarious Surgical System, a single-port surgical robot that virtually transports surgeons inside the patient to perform invasive surgery. The company was founded in 2014 and is headquartered in Waltham, Massachusetts.
Note: This website is maintained by Upturn Corporation, which is an investment adviser registered with the U.S. Securities and Exchange Commission. Such registration does not imply a certain level of skill or training. Investing in securities has risks. Past performance is no guarantee of future returns. No assurance is provided as to any particular investment return, and you may lose money using our services. You are strongly advised to consult appropriate counsel before making any investments in companies you learn about through our services. You should obtain appropriate legal, tax, investment, accounting, and other advice that takes into account your investment portfolio and overall financial situation. You are solely responsible for conducting due diligence on a potential investment. We do not affect trades for you. You will select your own broker through which to transact. Investments are not FDIC insured, they are not guaranteed, and they may lose value. Please see the Privacy Policy, Terms of Use, and Disclosure for more information.